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ABSTRACT
Hormone therapy targeting estrogen receptor (ER) is the principal treatment for 
ER-positive breast cancers. However, many cancers develop resistance to hormone 
therapy while retaining ER expression. Identifying new druggable mediators of ER 
function can help to increase the efficacy of ER-targeting drugs. Cyclin-dependent 
kinase 8 (CDK8) is a Mediator complex-associated transcriptional regulator with 
oncogenic activities. Expression of CDK8, its paralog CDK19 and their binding 
partner Cyclin C are negative prognostic markers in breast cancer. Meta-analysis 
of transcriptome databases revealed an inverse correlation between CDK8 and ERα 
expression, suggesting that CDK8 could be functionally associated with ER. We have 
found that CDK8 inhibition by CDK8/19-selective small-molecule kinase inhibitors, 
by shRNA knockdown or by CRISPR/CAS9 knockout suppresses estrogen-induced 
transcription in ER-positive breast cancer cells; this effect was exerted downstream 
of ER. Estrogen addition stimulated the binding of CDK8 to the ER-responsive GREB1 
gene promoter and CDK8/19 inhibition reduced estrogen-stimulated association of 
an elongation-competent phosphorylated form of RNA Polymerase II with GREB1. 
CDK8/19 inhibitors abrogated the mitogenic effect of estrogen on ER-positive cells 
and potentiated  the growth-inhibitory effects of ER antagonist fulvestrant. Treatment 
of estrogen-deprived ER-positive breast cancer cells with CDK8/19 inhibitors strongly 
impeded the development of estrogen independence. In vivo treatment with a 
CDK8/19 inhibitor Senexin B suppressed tumor growth and augmented the effects 
of fulvestrant in ER-positive breast cancer xenografts. These results identify CDK8 
as a novel downstream mediator of ER and suggest the utility of CDK8 inhibitors for 
ER-positive breast cancer therapy.
INTRODUCTION
Breast cancer is the most common female cancer 
and the second leading cause of cancer death in women 
[1]. Approximately 70% of breast cancers express estrogen 
receptor alpha (ERα) and are termed ER-positive [2, 3]. 
ERα, a member of the steroid hormone receptor family, 
mediates the biological effects of estrogens functioning 
as a ligand-inducible transcription factor that drives 
proliferation and survival of ER-positive breast cancer 
cells [4-6]. Hormone therapies have been developed 
which specifically inhibit ER signaling including 
selective estrogen receptor modulators (SERM) such as 
tamoxifen, selective estrogen receptor down-regulators 
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(SERD) such as fulvestrant, and aromatase inhibitors 
such as letrozole, which suppress estrogen synthesis [7]. 
However, many patients with ER-positive cancers do not 
respond to ER-targeting therapy, or they respond initially 
but develop progressive disease within 1-2 years due 
to the development of resistance. Identification of new 
“druggable” mediators of ER-regulated mitogenic effects 
could yield critical improvements in the treatment of 
ER-positive breast cancers [8]. In the present study, we 
have identified transcription-regulating oncogenic cyclin-
dependent kinase CDK8 as a novel druggable mediator of 
ER signaling.
CDK8 and its closely related paralog CDK19 (80% 
identity) are transcription-regulating serine/threonine 
kinases that, unlike better-known members of the CDK 
family (such as CDK1, CDK2 or CDK4/6), do not mediate 
cell cycle progression [9]. CDK8 or CDK19, together with 
their binding partner Cyclin C and MED12 and MED13 
proteins, form the CDK module of transcriptional Mediator 
complex. The CDK module regulates transcription through 
several different mechanisms, including phosphorylation 
of the C-terminal domain of RNA Polymerase II in a 
gene-specific context, which enables the elongation of 
transcription of newly activated genes [10, 11]. Since 
CDK8 activity is not generally required for transcription, 
CDK8 deletion in young adult mouse tissues did not 
induce any gross or histopathological abnormalities [12] 
and small-molecule CDK8 kinase inhibitors produced no 
detectable toxicity at therapeutically active doses [13, 14]. 
CDK8 activity has been implicated in regulating 
transcription in several pro-carcinogenic signaling 
pathways including Wnt/β-catenin [15] and TGFβ/BMP 
pathways [16]. CDK8 has been identified as an oncogene, 
which is amplified in many colorectal cancers [15]. 
CDK8 has also been implicated in melanomagenesis [17], 
pancreatic cancer [18] and associated with the cancer stem 
cell phenotype [19]. Our work has identified CDK8/19 
as a mediator of damage-induced tumor-promoting 
paracrine activities of both tumor and normal cells; as a 
consequence, CDK8/19 inhibitors increase the efficacy of 
chemotherapy in vivo [13].
In the same study, we found that higher expression 
of CDK8, CDK19 and Cyclin C is associated with shorter 
relapse-free survival in human breast cancers [13]. More 
recently, we demonstrated that the same correlations are 
observed in all principal subtypes of breast cancer and 
their predictive value is much higher for patients who 
subsequently underwent systemic adjuvant therapy (either 
hormonal or chemotherapy), suggesting that CDK8 can 
impact the failure of systemic treatment in breast cancer. 
We also found that higher CDK8 protein expression was 
observed in invasive ductal carcinomas relative to non-
malignant mammary tissues [20]. A correlation of CDK8 
expression with tumor status, nodal metastasis and stage 
in breast cancer has also been reported by Xu et al., whose 
study suggested that CDK8 plays a role in mammary 
carcinogenesis [21].
We have now discovered that CDK8 acts as a 
downstream mediator of transcriptional and mitogenic 
signaling by ER and that inhibition of CDK8 suppresses 
ER-positive breast cancer cell growth in vitro and in vivo, 
potentiates hormone therapy and prevents the emergence 
of estrogen independence. These findings identify CDK8 
as a promising new target to exploit in ER-positive breast 
cancer treatment. 
RESULTS
Bioinformatics suggests an association of CDK8 
with estrogen receptor signaling
We have extended our previous analysis of 
CDK8 expression in breast cancer [20] and investigated 
correlations between CDK8 and ER expression using a 
microarray database of 3,491 breast cancer patients. Mean 
CDK8 expression was 1.79-fold higher among 807 ER-
negative patients than among 2,036 ER-positive patients 
(p < 2E-118, t-test). Figure 1A shows a very strong 
negative correlation between ESR1 (ERα) and CDK8 
gene expression among breast cancer samples. Similar 
inverse correlations with ESR1 were observed for the 
CDK8 paralog CDK19 and their binding partner Cyclin 
C (Figure 1B, 1C). These observations, together with a 
known function of CDK8 as a potentiator of another 
steroid hormone receptor, the thyroid hormone receptor 
[22], suggested to us that CDK8/19 could also be acting 
as a positive effector of ER. If this were the case, an 
increase in CDK8/19 could enable cells with lower ER 
levels to utilize estrogen stimulation more efficiently, thus 
accounting for the inverse correlation. Interestingly, MYC, 
which has previously been identified as a positive mediator 
of ER activity [23], also shows an inverse correlation 
with ESR1 (Figure 1D). Thus, we hypothesized that ER 
signaling in ER-positive breast cancer could be attenuated 
through CDK8/19 inhibition.
Inhibition of CDK8/19 attenuates estrogen-
induced transcription
The addition of the selective CDK8/19 inhibitor 
Senexin A [13] resulted in a dose-dependent decrease 
in luciferase activity in T47D-ER/Luc cells, expressing 
firefly luciferase under control of an ER-dependent ERE-
containing promoter, suggesting that CDK8/19 potentiates 
ER-mediated transcription (Figure 2A). Senexin A did 
not affect ERα protein expression or phosphorylation at 
S118 (Figure 2B), indicating that CDK8/19 inhibition 
suppresses ER-mediated transcriptional activity 
downstream of ER.
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Co-administration of Senexin A with estradiol (E2) 
in ER-positive MCF7 cells prevented estrogen-mediated 
induction of mRNA of GREB1, CXCL12 and TFF1 
(Figure 3A), the three genes that were previously reported 
to be the most common transcriptional targets of ER in 
different ER-positive breast cancer cell lines [24]. Similar 
results were also found in BT474 and T47D-ER/Luc cells 
(Figure 3A). In contrast to the effect of estrogen addition, 
Senexin A treatment did not inhibit expression of these 
three genes in cells growing in estrogen-containing full 
media, although it decreased the upregulation of GREB1 
that was observed upon addition of estradiol to such media 
(Figure 3B).
Knockdown or knockout of CDK8 suppresses 
estrogen-induced gene expression
Using lentiviral vector-based shRNA against CDK8 
in BT474 cells, a stable CDK8 knockdown cell line was 
established (BT474-shCDK8). Knockdown of CDK8 
diminished CDK8 protein expression relative to BT474 
PLKO.1 control cells, concomitantly increasing the 
expression of its paralog CDK19 and without altering 
ERα expression. Similar effects were also observed in a 
CRISPR-Cas9 based CDK8 knockout derivative of BT474 
cell line (CRISPR-CDK8) (Figure 4A). Gene expression 
analysis of both BT474-shCDK8 and CRISPR-CDK8 cells 
Figure 1: CDK8/19 expression inversely correlates with estrogen receptor expression. Correlation between the expression of 
ESR1 (ERα) and A. CDK8, B. CDK19, C. CCNC and D. MYC in 3,491 breast cancers. Each graph shows the average values for 35 bins 
of 100 samples, arranged by ESR1 expression. 
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Figure 2: Effects of CDK8/19 inhibition on ER. A. Luciferase expression from ER-dependent consensus promoter in T47D-ER/
Luc reporter cells deprived of estrogen for 72 hours prior to treatment with 10 nM estradiol (E2) and increasing concentrations of Senexin 
A for 18 hours. RLU refers to relative luciferase units as a percentage of control. B. Western blot analysis of phospho-ER (Ser118) and ER 
expression in T47D-ER/Luc reporter cells deprived of estrogen for 72 hours prior to treatment with 10 nM estradiol (E2) in the presence 
or absence of 2.5 µM Senexin A for 15 mins and 6 hours. Loading was normalized using GAPDH and densitometry was performed using 
ImageLab software. 
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Figure 3: Effects of Senexin A on ER-regulated gene expression. A. q-PCR analysis of ER-responsive gene expression of 
GREB1, CXCL12, and TFF1 in estrogen-deprived MCF7, BT474 and T47D-ER/Luc cells treated with E2 (10 nM) and Senexin A (2.5 µM) 
(SNXA) for 6 and 12 hours. * denotes P < 0.05 and ** denotes P < 0.01. B. q-PCR analysis of GREB1, CXCL12, and TFF1 gene expression 
in MCF7 cells cultured in regular media (without prior estrogen deprivation) following treatment with 10 nM estradiol (E2) and 2.5 µM 
Senexin A (SNXA) alone and in combination for 12 hr. 
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Figure 4: Effects of CDK8 knockdown and knockout on ER-regulated gene expression. A. shRNA knockdown of CDK8 
in BT474 cells (BT474 shCDK8) and CRISPR-Cas9 knockout of CDK8 in BT474 cells (BT474 CRISPR-CDK8) analyzed for protein 
expression by western blotting. B. q-PCR analysis of the effects of E2 on GREB1 gene expression in estrogen-deprived BT474 shCDK8 
compared to BT474 PLKO.1 and in BT474 CRISPR-CDK8 compared to BT474 CRISPR-CTRL cells.
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revealed that in contrast to vector control-transfected cells, 
lack of CDK8 renders estradiol incapable of inducing 
GREB1 and abolishes the effect of Senexin A on GREB1 
expression (Figure 4B). These results confirm the data 
obtained with CDK8/19 kinase inhibitor and suggest that 
CDK8 alone mediates ER signaling in BT474 cells. 
Inhibition of CDK8/19 has global effects on 
estrogen-induced transcription
To determine transcriptomic effects of CDK8/19 
inhibition on ER-regulated gene expression we performed 
microarray analysis of estrogen-deprived MCF7 cells 
treated with E2 and/or Senexin A. Figure 5A shows a 
heatmap generated for 45 genes that were altered over 
2-fold (p < 0.05) by estrogen treatment; all but three 
of these genes were induced by estrogen. The effect of 
estrogen on the majority of those genes (64%; 29/45) 
was counteracted over 1.5-fold (p < 0.05) by Senexin A 
addition. Figure 5B shows qRT-PCR validation of the 
microarray data for PGR, EGR3, FOS, SKG1, RET, and 
RERG, all of which were induced by estrogen treatment 
while Senexin A addition significantly decreased this 
effect (only in the case of PGR, Senexin A inhibited gene 
expression even without estrogen addition). On the other 
hand, ANG gene expression was decreased by estrogen 
treatment and Senexin A counteracted this effect (Figure 
5B).
CDK8 is recruited to GREB1 gene upon estrogen 
stimulation and mediates the association of 
elongation-competent phosphorylated form of 
RNA Polymerase II with GREB1
Chromatin immunoprecipitation (ChIP) analysis 
revealed that ERα binding at GREB1 promoter/enhancer 
regions (close to EREs, as previously reported [25, 26]) 
is increased following E2 treatment but not significantly 
affected by CDK8 kinase inhibition (Figure 6A). 
Remarkably, CDK8 is also strongly recruited to GREB1 
promoter/enhancer regions upon the addition of E2; this 
recruitment is also not significantly affected by Senexin A 
(Figure 6B; IgG control data are shown in Supplemental 
Figure 1A). In contrast to its effect on ER-inducible 
GREB1 gene, E2 had no effect on either ERα or CDK8 
binding to a control housekeeping gene, GAPDH (Figure 
6A-6B). To test whether decreased E2-dependent gene 
expression in response to CDK8 inhibition is due to an 
effect on Pol II CTD phosphorylation at S2 (S2P), which 
enables the elongation of transcription, we performed ChIP 
for RNA Pol II S2P on estrogen-deprived MCF7 cells 
treated with E2 alone or in combination with Senexin A. 
E2 treatment strongly increased S2P binding along the full 
length of GREB1, indicating elongation of transcription, 
while Senexin A significantly decreased the amount of S2P 
associated with GREB1 in E2-treated cells. In contrast, 
Senexin A had no significant effect on S2P binding and 
distribution along the housekeeping GAPDH gene, in 
agreement with the lack of general CDK8 requirement 
for transcription (Figure 6C; IgG control data are shown 
in Supplemental Figure 1B). These results suggest that 
inhibition of CDK8 kinase activity results in decreased 
E2-dependent transactivation by inhibiting E2-induced 
S2 phosphorylation of the Pol II CTD and its associated 
transcriptional elongation of ER-dependent genes. 
Inhibition of CDK8/19 suppresses the mitogenic 
effect of estrogen 
We asked whether decreased E2-dependent 
transcription in response to CDK8 inhibition would 
correspond with a decrease in estrogen-mediated 
mitogenic signaling. The addition of estradiol to estrogen-
depleted MCF7, BT474 and T47D-ER/Luc cells induced 
robust cell proliferation but this effect of estradiol was 
abolished by the co-administration of Senexin A (Figure 
7A). MCF7-Veh cells are a MCF7 derivative that was 
adapted to grow in the absence of estrogen and is only 
weakly stimulated by estrogen [24]. Senexin A had only a 
weak effect on estrogen-stimulated growth of these cells, 
reducing their growth to the level of estrogen-untreated 
cells, in contrast to a much stronger effect on the parental 
MCF7 cells (Figure 7A), indicating that the anti-mitogenic 
effects of CDK8/19 inhibition were mediated primarily 
through ER signaling. 
Senexin A also had a dose dependent growth 
inhibitory effect on ER-positive cells in regular (estrogen-
containing) media (Figure 7B). Flow cytometric analysis 
showed no apparent increase in membrane-permeable 
(dead) cells after Senexin A treatment (Supplemental 
Figure 2), indicating that its growth-inhibitory effect 
was cytostatic rather than cytotoxic. We also evaluated 
the effects of Senexin B, a newly optimized derivative 
of Senexin A, which has the same high selectivity for 
CDK8/19 and is more potent than Senexin A [27]. As 
expected, Senexin B was more efficient in inhibiting 
cell growth in the three cell lines compared to Senexin A 
(Figure 7B). 
CDK8/19 inhibitors prevent the emergence of 
long-term estrogen independence
Long-term culture of cells in the absence of 
estrogen mimics the effects of aromatase inhibition in cell 
culture and exposure of ER-positive cells to long-term 
estrogen deprivation (LTED) results in the emergence of 
cells which no longer require estrogen to maintain cell 
growth [28]. We sought to determine whether combining 
CDK8/19 inhibition with LTED would slow down or 
prevent the development of estrogen independence in 
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Figure 5: Transcriptomic analysis of the effects of CDK8/19 inhibition on ER signaling. A. Heatmap of the expression of 
genes altered > 2-fold (p < 0.05) by estrogen treatment, based on microarray analysis performed on estrogen-deprived MCF7 cells treated 
with either 10 nM estradiol (E2), 2.5 µM Senexin A (SNXA) or a combination of E2 and Senexin A (E2+SNXA) for 12hr. B. q-PCR 
validation of estrogen regulated genes in MCF7 cells treated with E2 (10 nM) and Senexin A (2.5 µM) for 12 hours. * denotes P < 0.05 and 
** denotes P < 0.01.
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Figure 6: Chromatin immunoprecipitation (ChIP) analysis of ER regulation by CDK8/19. ChIP for ER A., CDK8 B. and 
RNA-PolII S2P C. was performed on estrogen-deprived MCF7 cells treated with E2 (10 nM) and Senexin A (2.5 µM) for 12 hours. ChIP 
was followed by q-PCR of different regions of GREB1 and GAPDH. The schematics in A. show transcriptional start site (TSS), estrogen 
receptor binding elements (EREs) and primer binding locations used in A. and B. (indicated by black bars, with primer positions are listed 
as the distance from the TSS (Kb)). The schematics in C show the primer binding locations as the distance from the TSS of the respective 
gene (Kb). * denotes P < 0.05.
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Figure 7: Anti-mitogenic effects of CDK8/19 inhibition in ER-positive breast cancer cells. A. Effect of 10 nM estradiol (E2) 
in the presence and absence of 5 µM Senexin A on the growth of estrogen deprived BT474, T47D-ER/Luc, MCF7 and MCF7-Veh cells 
over 5 days. B. Effects of CDK8/19 inhibitors on the growth of MCF7, BT474 and T47D-ER/Luc cells in estrogen-containing media. Cells 
were treated with a range of Senexin A and Senexin B concentrations and the cell growth was measured by cell counting on days 3, 5 and 
7 after treatment.
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ER-positive breast cancer cells. To assess this, MCF7, 
BT474 and T47D-ER/Luc cells were maintained under 
estrogen depleted conditions and then treated with a range 
of inhibitors that were previously shown to inhibit the 
development of estrogen independence [29], including a 
PI3K inhibitor GDC0941 (pictilisib), a HER2 inhibitor 
lapatinib and a mTOR inhibitor RAD001 (everolimus), 
as well as Senexin A and Senexin B. CDK8/19 inhibitors 
strongly reduced the emergence of estrogen independent 
cells (Figure 7), with a more potent Senexin B showing a 
stronger effect than Senexin A. CDK8/19 inhibitors were 
more effective than mTOR inhibitors or HER2 inhibitors 
(except for the HER2-positive BT474 cells), and only the 
PI3K inhibitor, the only cytotoxic agent in this set, was 
as efficacious as the non-cytotoxic Senexin B (Figure 8). 
Hence, CDK8/19 inhibition prevents the development of 
estrogen independence in ER-positive breast cancer cells.
Inhibition of CDK8/19 suppresses tumor growth 
and potentiates the effect of fulvestrant in vitro 
and in vivo
To examine whether CDK8/19 inhibition may 
potentiate the effects of ER-inhibiting drugs in estrogen-
dependent breast cancer, MCF7, T47D-ER/Luc and BT474 
were treated with Senexin A or B, alone or in fixed ratio 
combinations with a SERD fulvestrant. Senexin A and 
Senexin B both showed synergy with fulvestrant in MCF7, 
T47D-ER/Luc and BT474 cells (Figure 9A and Table 1), 
with the most efficacious effect occurring in BT474 cells 
when Senexin B was combined with fulvestrant giving a 
Combination Index (CI) value of 0.16 ± 0.08 (Table 1). 
To determine whether the tumor-suppressive effects 
of CDK8 inhibition and potentiation of fulvestrant activity 
observed in vitro would be recapitulated in vivo, we treated 
mice bearing MCF7 xenograft tumors with a vehicle, 
Senexin B or fulvestrant alone or with a combination of 
Senexin B and fulvestrant over a period of 40 days. Both 
fulvestrant and Senexin B when used alone produced a 
significant decrease in tumor volume (Figure 9B) without 
apparent toxicity or significant effects on mouse body 
weight (Figure 9C). A significant decrease in tumor 
volume (p = 0.0023) (Figure 9B) and terminal tumor 
weights (p = 0.0049) (Figure 9D) between fulvestrant 
alone and fulvestrant in combination with Senexin B was 
also observed, indicating that the combination treatment 
is tolerable and more effective at decreasing tumor growth 
compared to ER-targeted single agent therapy. Analysis 
of ER-regulated GREB1 mRNA expression in tumors 
of different groups indicated that GREB1 expression 
was significantly suppressed by Senexin B treatment 
alone (p = 0.033). When Senexin B was combined with 
fulvestrant there was further suppression of GREB1 
expression compared to fulvestrant alone (p = 0.025) 
(Figure 9E). These results demonstrate that CDK8/19 
inhibition suppresses ER-positive breast cancer growth 
and potentiates the growth-inhibitory effect of fulvestrant 
in vitro and in vivo. 
DISCUSSION
Transcription-regulating kinases CDK7, CDK9 and 
CDK8/19 have become actively pursued targets in cancer 
therapy, due in part to their effects on super-enhancers 
that develop during carcinogenesis and become essential 
for the survival of tumor cells [14, 30]. A number of 
groups are developing inhibitors of CDK8/19 Mediator 
kinase [31], which show numerous effects on oncogenic 
transcriptional signaling [31, 32] and potentiate the effects 
of chemotherapeutic drugs by blocking drug-induced 
transcriptional activation of proteins associated with drug 
resistance and tumor progression [13]. As single agents, 
however, CDK8/19 kinase inhibitors showed little or no 
growth-inhibitory effect in the majority of tested tumor 
and normal cell types [13]. While the linkage of CDK8 to 
carcinogenesis was originally discovered in colon cancer 
[15], CDK8/19 kinase inhibitors did not inhibit the growth 
of CDK8-overexpressing colon cancer cells [14, 33]. 
The first evidence for single-agent activity of CDK8/19 
inhibitors was reported for a subset of leukemia cell lines, 
where CDK8/19 inhibition had a strong anti-proliferative 
effect through hyper-activating super-enhancer-associated 
genes in such leukemias [14]. We [13, 20] and others 
[21] have previously shown that CDK8/19 is a negative 
prognostic marker in breast cancer. In the present study, 
we have discovered that CDK8 inhibition also inhibits ER 
Table 1: The effects of fulvestrant and Senexin A or B when combined in a fixed ratio on MCF7, BT474 and T47D-ER/
Luc cells measured by MTT assay. 
Cell Line Drug 1 Drug 2 drug combination ratio CI 
MCF7 Senexin A Fulvestrant 50 nM : 1 nM 0.39 ± 0.17
Senexin B Fulvestrant 50 nM : 1 nM 0.19 ± 0.11
T47D-ER/Luc Senexin A Fulvestrant 50 nM : 1 nM 0.49 ± 0.36
Senexin B Fulvestrant 50 nM : 1 nM 0.20 ± 0.02
BT474 Senexin A Fulvestrant 50 nM : 1 nM 0.44 ± 0.12
 Senexin B Fulvestrant 50 nM : 1 nM 0.16 ± 0.08
CI values were calculated at 50% effective dose (ED50) using Compusyn software whereby values <1 indicate additive effect, 
values < 0.7 indicate synergism and values <0.3 indicate strong synergism. 
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Figure 8: Effects of CDK8/19 inhibition on the emergence of estrogen independent cells. Long term growth of MCF7, 
BT474 and T47D-ER/Luc cells in estrogen deprived media in the presence of Senexin A (5 µM), GDC0941 (1 µM), Lapatinib (1 µM), 
RAD001 (200 nM) and Senexin B (5 µM). Media and drug were replenished every 3-4 days. Cells were fixed and stained with crystal violet 
after 15 days for MCF7, 20 days for BT474 and 39 days for T47D-ER/Luc. Additional treated plates of cells were counted and cell counts 
expressed relative to untreated cells.
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Figure 9: Effects of a CDK8/19 inhibitor and fulvestrant on ER-positive breast cancer cell growth in vitro and in vivo. 
A. Growth inhibitory effects of Senexin B, fulvestrant and a 50:1 mixture of Senexin B and fulvestrant in MCF7, BT474 and T47D-ER/
Luc. B. Tumor volume changes, C. relative mouse body weight changes, and D. terminal tumor weights of xenografts generated by 
subcutaneous injection MCF7 cells in NSG mice (n = 11-13 per group), treated with vehicle control, Senexin B (100 mg/kg, twice daily), 
fulvestrant (5 mg/kg, twice weekly) or a combination of Senexin B and fulvestrant, over 40 days. Data are expressed as Mean ± SEM. E. 
q-PCR analysis of GREB1 gene expression in RNA extracted from MCF7 xenograft tumors.
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signaling and suppresses the growth of ER-positive breast 
cancer cells, the most common type of breast cancer, in 
vitro and in vivo.  
Inhibition of ER-mediated transcription by selective 
small-molecule CDK8/19 inhibitors Senexin A and 
Senexin B was demonstrated both at the level of the ER-
responsive promoter and endogenous gene expression, in 
three different ER-positive cell lines. Microarray analysis 
suggested that the effect on ER-regulated genes is global, 
since the effect of estrogen on most ER-regulated genes 
was attenuated by CDK8 inhibition. Although Senexin A 
and Senexin B, like all other reported CDK8 inhibitors, 
inhibit both CDK8 and CDK19, CDK8 appears to be 
sufficient for the effect on ER-dependent transcription at 
least in some ER-positive cell lines, since knockdown or 
knockout of CDK8 alone was sufficient to suppress both 
ER-dependent transcription and the effects of CDK8/19 
kinase inhibitors on ER-regulated gene expression in 
BT474 cells. Remarkably, CDK8 inhibition prevented 
the induction of ER-responsive genes upon estrogen 
addition to estrogen-depleted cells but did not inhibit such 
genes in cells maintained in the presence of estrogen. 
The requirement for CDK8 in de novo gene expression 
induction but not for sustained expression of genes that 
are already actively transcribed is in agreement with 
the previous reports on the effects of CDK8 on other 
transcription-initiating factors [10, 11].
The effect of CDK8 on transcription appears to be 
exerted downstream of ER, since CDK8 does not affect 
the levels of ERα protein, estrogen-induced changes 
in ERα stability or its phosphorylation at S118, a major 
but not the sole site of ERα phosphorylation in response 
to estrogen stimulation [34, 35]. CDK8 inhibition also 
did not affect the recruitment of ERα to the promoter/
enhancer regions of ER-regulated GREB1 gene, indicating 
that CDK8 exerts its effect downstream of ER. We have 
found here that CDK8 is recruited, along with ER, to 
the GREB1 promoter upon estrogen stimulation but 
this recruitment was also unaffected by CDK8 kinase 
inhibition. On the other hand, CDK8 inhibition decreased 
estrogen-stimulated binding of the elongation-competent 
CTD-phosphorylated S2P form of Pol II, indicating 
that this phosphorylation provides a mechanism for ER 
potentiation of CDK8, in agreement with the previously 
described effects of CDK8 on the transcriptional serum 
network and HIF1A-induced transcription [10, 11]. 
Inhibition of ER-mediated transcriptional signaling 
by CDK8/19 inhibitors was associated with a strong 
inhibition of the mitogenic effect of estrogen in ER-
positive breast cancer cell lines and with cytostatic growth 
inhibition of ER-positive cells in estrogen-containing 
media. The anti-mitogenic effect of CDK8/19 inhibitors 
appears to be mediated primarily or exclusively by ER 
signaling, since this effect was drastically reduced in a 
cell line selected for estrogen independence (MCF7-Veh). 
Since SERDs act directly on ER and CDK8 
acts downstream of it, combining SERDs with CDK8 
inhibitors could have a combinatorial or synergistic effect. 
(In contrast to SERDs, the tumor-suppressive activity 
of SERMs, such as tamoxifen, involves ER-mediated 
transcriptional signaling which is modified by this drug 
[36], and CDK8/19 inhibition could potentially interfere 
with the effect of SERMs by suppressing ER signaling.) 
Indeed, a SERD fulvestrant showed a positive interaction 
with CDK8/19 inhibitors, both in vitro and in vivo. 
Interestingly, while the in vitro growth-inhibitory effect of 
fulvestrant alone was much stronger than that of Senexin 
B alone, the in vivo effects of the two compounds were 
similar, possibly reflecting a role of CDK8/19 in tumor-
stromal interactions [13]. Importantly, the combination of 
Senexin B and fulvestrant showed no apparent toxicity, 
while producing a stronger tumor-suppressive effect than 
either drug alone.
We have also found that CDK8/19 inhibitors prevent 
the development of estrogen independence upon long-
term estrogen deprivation (which mimics the effects of 
aromatase inhibitors) in all three tested ER-positive cell 
lines. This effect is probably due to the general role of 
CDK8 in mediating transcriptional reprogramming by 
enabling the elongation of transcription of newly activated 
genes [9, 10]. CDK8/19 inhibitors therefore may suppress 
transcriptional changes associated with the activation 
of the compensatory signal transduction pathways 
that complement ER signaling, leading to estrogen 
independence. The ability to prevent the development 
of estrogen independence, a major clinical problem in 
hormone therapy of ER-positive cancers, may offer the 
greatest therapeutic benefit in the future clinical use of 
CDK8/19 inhibitors. 
MATERIALS AND METHODS
Cell culture and reagents
MCF7 and BT474 cells were obtained from ATCC 
(Manassas, VA, USA); T47D-ER/Luc, which expresses 
luciferase from an ER-dependent consensus promoter, 
was obtained from Signosis (Santa Clara, CA, USA); the 
generation of MCF7-Veh cells was previously described 
[28]. BT474 cells were maintained in RPMI-1640 
(ThermoFisher Scientific, Waltham, MA, USA) with 10% 
fetal bovine serum (FBS) (Atlanta Biologics, Flowery 
Branch, GA, USA), 1% penicillin-streptomycin and 2mM 
L-glutamine (VWR, Radnor, PA, USA). T47D-ER/Luc 
cells were maintained in the same media as BT474 cells 
with 75 µg/ml of G418 (Sigma-Aldrich). MCF7 cells were 
maintained in DMEM-high glucose media (ThermoFisher 
Scientific) with 10% FBS, 1% penicillin-streptomycin 
and 2 mM L-glutamine, 1 mM sodium pyruvate (Sigma-
Aldrich) and 5 mg insulin (Sigma-Aldrich). For estrogen 
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deprivation (ED), BT474 and T47D-ER/Luc cells were 
maintained in phenol-red free RPMI-1640 with 10% 
FBS and MCF7 cells were maintained in phenol-red 
free DMEM/Hams F12 with 10% FBS (with the same 
additives as indicated above). After three days, cells were 
plated in either phenol-red free RPMI-1640 or phenol-
red free DMEM/Hams F12 with 10% charcoal-dextran-
stripped FBS (ThermoFisher Scientific) (with all additives 
indicated above) and allowed to grow for 24-72 hours 
prior to treatment. MCF7-Veh cells were maintained 
under constant ED conditions. All cell lines were routinely 
confirmed to be free of Mycoplasma (MycoAlert PLUS 
mycoplasma detection kit (Lonza, Walkersville, MD, 
USA) and were authenticated by STR profiling by the 
University of Arizona Genetic Core (Tucson, AZ, USA) 
in August 2016. Estradiol (E2) was obtained from Sigma-
Aldrich (St Louis, MO, USA), Senexin A and Senexin B 
dimaleate were from Senex Biotechnology (Columbia, SC, 
USA), GDC0941 (pictisilib) and RAD001 (everolimus) 
were from Selleck Chemicals (Houston, TX, USA), 
Lapatinib was from LC Laboratories (Woburn, MA, USA), 
Fulvestrant was from ApexBio (Houston, TX, USA) . 
Gene expression correlation analysis
Correlation analysis between expression levels of 
pairs of genes in the Affymetrix microarray dataset of 
3,491 breast cancers [37], was carried out using Microsoft 
Excel. Signal values for 3,491 samples were arranged 
in ascending order for the first gene and divided into 35 
bins of 100 samples (91 samples in the last bin). The 
median signal values for the first and the second genes 
were computed for each bin and plotted on log(2) scale. 
R-squared values for correlation were computed for Power 
regression.
Promoter assay
T47D-ER/Luc cells were plated under ED 
conditions and after 48-72 hours were treated with a range 
of concentrations of Senexin A, then one hour later with 10 
nM E2. Cells were then incubated for a further 18 hours, 
trypsinized, counted and lysed in lysis buffer (Promega, 
Madison, WI, USA). Luciferase was measured with 
Dual-Luciferase E1960 Reporter Assay (Promega) and 
fluorescence read on FluroStar Optima 960 plate reader 
using Optima software and normalized by cell number.
Long term estrogen deprivation assays
MCF7, BT474 and T47D-ER/Luc cells were seeded 
into duplicate 6-well plates under ED conditions. After 
24 hours cells were treated with: Senexin A (5 µM), 
GDC0941 (pictisilib) (1 µM), Lapatinib (1 µM), RAD001 
(everolimus) (200 nM) and Senexin B (5 µM), with DMSO 
as a vehicle control. Media and drug were replenished 
every 3-4 days. After 15 days (MCF7), 20 days (BT474) 
or 39 days (T47D-ER/Luc) one plate was stained with 
Crystal violet and imaged using a ChemiDoc™ Imaging 
system. Cells on the remaining plate were trypsinized and 
counted.
Mitogenic stimulation assays
Cells were seeded in 6-well plates under ED 
conditions; after 24 hours an initial cell count was 
performed (Day 0). Cells were then treated with 10 nM 
E2 and/or 5 µM Senexin A and cell counts were performed 
on days 1, 3 and 5 after treatment. Cells were counted in 
triplicate and cell numbers were plotted relative to control 
cells.
Synergy assays
Cells were seeded into 96-well plates and after 24 
hours plates were treated with Senexin A or B (0 - 10 µM) 
and fulvestrant (0 - 200 nM) alone or together in a fixed 
ratio of 50:1. After 7 days cell proliferation was measured 
by MTT assay (Sigma-Aldrich). 
Western blotting
Protein (50 µg) was resolved on 8% Express-
Plus PAGE gels in Tris-MOPS (SDS) running buffer 
(GenScript, Piscataway, NJ, USA), transferred to PVDF 
membranes and incubated at 4°C overnight with primary 
antibodies: CDK8 (sc-1521, SantaCruz, Santa Cruz, CA, 
USA), CDK19 (HPA007053, Sigma-Aldrich), ER (sc-543, 
SantaCruz), phospho-ER Ser118 (sc-101675, SantaCruz) 
and GAPDH (#5174, Cell Signaling Technology, Danvers, 
MA, USA) followed by either anti-goat (sc-2020, 
SantaCruz), anti-rabbit (#31460, ThermoFisher Scientific) 
or anti-mouse (31430, ThermoFisher Scientific) secondary 
antibodies. Bands were visualized with Western Lighting 
Plus ECL detection reagent (Perkin Elmer, Waltham, MA, 
USA) using ChemiDoc Touch™ (BioRad). Images were 
analyzed and densitometry performed using ImageLab 
software (Biorad).
RNA extraction, reverse transcription, and q-PCR 
Cells were seeded in 6-well plates under ED 
conditions and treated with 10 nM E2 and/or 2.5 µM 
Senexin A for 6 and 12 hours. Total RNA was extracted 
using RNAeasy Mini Kit (Qiagen, Hilden, Germany) 
and 1 µg of total RNA was used to generate cDNA using 
iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). 
Gene expression was quantified using iTaq Universal 
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SYBR green super mix on a CFX384 Real time system 
(BioRad). Primers used for real-time PCR are listed in 
Supplemental Table 1. 
ChIP assays
Estrogen-deprived MCF7 cells treated with either 
10 nM estradiol (E2), 2.5 µM Senexin A or a combination 
of E2 and Senexin A for 12hr and ChIP assays were 
performed as previously described [38]. Briefly, cells 
were fixed with 1% (v/v) formaldehyde, harvested for 
whole cell lysate preparation and immunoprecipitation 
was performed with 2 µg of antibodies against CDK8 
(sc-1521, SantaCruz), ER-α (sc-543, SantaCruz), RNA-
Pol II-S2P (C152000005, Diagenode) and rabbit and goat 
IgG (sc-2027, sc-2028, Santa Cruz) and enriched DNA 
was analyzed by q-PCR with ChIP primers (Supplemental 
Table 2).
Generation of CDK8 knockout and knockdown cells
BT474 CDK8 CRISPR-Cas9 knockout cells were 
generated by lentiviral transduction using lentiCRISPR 
v2 (#52961 Addgene) with the sgRNA targeting human 
CDK8 (TGCAGCCCTCGTATTCAAACAGG) (designed 
online using www.crispr.mit.edu and cloned by Viral 
Vector Core (University of South Carolina School of 
Medicine)). Parental vector (no-sgRNA) was used a 
negative control. BT474 CDK8 knockdown cells were 
generated using pLKO.1 lentiviral virus expressing 
CDK8 shRNAs (GAACCTGGTATGGGCCATGAG, 
from Sigma-Aldrich). All virus production was performed 
in HEK 293FT cells (Invitrogen, Carlsbad, CA, USA). 
Briefly, at T = 0 cells were transiently transfected with 2 
ml of a calcium phosphate precipitation mixture containing 
pMD2.G (3 μg/ml), psPAX2 (6μg/ml) (Addgene) and 12 
μg/ml of pLKO.1 transfer plasmid. At T = 16h, medium 
was replaced. At T = 24h, 40h and 48h medium was 
collected, concentrated by overnight centrifugation and 
re-suspended at a concentration of 1000X in PBS. BT474 
cells were infected with MOI = 4 (shCDK8) and MOI = 
5 (sgCDK8) followed by 72h puromycin selection (2 µg/
ml). Both shRNA knockdown and CRISPR-Cas9 knockout 
were performed by the Functional Genomics Core 
(FGC) of the COBRE Center for Targeted Therapeutics, 
University of South Carolina.
Microarray analysis
Cells were seeded in biological duplicates under 
ED conditions, treated with 2.5 µM Senexin A for 24 
hours and then treated with 10 nM E2 for 12 hours. Total 
RNA was extracted as described above and RNA quality 
was tested using Bioanalyser (Agilent, Santa Clara, CA, 
USA). Samples were analyzed at the FGC using dual-
channel Agilent arrays. Data analysis was performed using 
limma package in R [39, 40]. Heatmap and unsupervised 
clustering (using Euclidean distance and Ward clustering) 
for genes affected at least 2-fold (p < 0.05) by E2 treatment 
were also performed in R using gplots package [41]. The 
microarray data in this manuscript is available on the GEO 
database (GSE93193). A subset of identified genes was 
validated in biological triplicates by q-PCR. 
In vivo xenograft experiments
All animal studies were performed according 
to guidelines established by the Institutional Animal 
Care and Use Committee (IACUC) at the University 
of South Carolina (Columbia, SC). MCF7 cells (1x107 
in 50% matrigel) were injected subcutaneously into the 
flanks of fifty female NSG mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ: Stock No: 005557, Jackson Laboratory, 
Bar Harbor, ME, USA) bearing a 0.36 mg 17β-estradiol 
pellet (Innovative Research of America, Sarasota, FL, 
USA). Once tumors reached 100-200 mm3 volume, 4 
groups of mice (n = 11-13) were treated with vehicle, 
Senexin B dimaleate (100 mg/kg; twice daily, oral gavage 
in 6.25% 2-Hydroxypropyl-β-cyclodextrin, 1% Dextrose 
buffer) alone or in combination with fulvestrant (5 mg/
mouse; s.c; once/week). Tumor volumes were measured 
twice weekly with calipers and volumes were calculated 
using the formula V = W2 x L/2. After 40 days mice were 
euthanized, tumors were excised and weighed. Tumor 
fragments measuring 20-30 mg were homogenized in 700 
µl of Qiazol reagent and QiaShredder columns, and RNA 
extracted using chloroform and the RNAeasy Mini Kit 
(Qiagen), for q-PCR analysis. 
Statistical analysis
All results were presented as mean ± standard 
deviation of 4-8 parallel assessments. Similar results 
were obtained from a minimum of two independent 
experiments. Combination index (CI) values were 
calculated for MTT combination treatments, using 
CompuSyn synergy software based on the drug 
combination principles of Chou-Talalay [42], providing 
a quantitative definition for additive effect (CI = 1), 
synergism (CI < 1), and antagonism (CI > 1) in drug 
combinations. Statistical significance was tested using 
two-sided Student T-tests and populations were considered 
significantly different at P < 0.05.
ACKNOWLEDGMENTS
We appreciate the help of Dr. Boris Kantor and 
the Viral Vector Core, University of South Carolina 
(USC) School of Medicine for CDK8 sgRNA constructs, 
and of the Functional Genomics and Microscopy and 
Flow Cytometry Cores of the USC Center for Targeted 
Therapeutics for assistance with lentiviral transduction 
and flow cytometric analysis.
Oncotarget12574www.impactjournals.com/oncotarget
CONFLICT OF INTEREST 
EVB is a consultant, MC is a contract PI 
and a consultant and IBR is the President of Senex 
Biotechnology, Inc.
FINANCIAL SUPPORT
NIH P20 GM 109091 (EVB, IBR), IRG-13-043-
01 ACS and NIH 30 GM103336 (EVB), and Susan G. 
Komen® postdoctoral fellowship PFD 15329865 (MMcD).
Editorial note 
This paper has been accepted based in part on peer-
review conducted by another journal and the authors’ 
response and revisions as well as expedited peer-review 
in Oncotarget.
REFERENCES
1. The American Cancer Society. What are the key statistics 
about breast cancer? 2016.
2. Clark GM, Osborne CK, McGuire WL. Correlations 
between estrogen receptor, progesterone receptor, and 
patient characteristics in human breast cancer. Journal of 
Clinical Oncology. 1984; 2: 1102-1109.
3. Keen JC, Davidson NE. The biology of breast carcinoma. 
Cancer. 2003; 97: 825-833.
4. Lim E, Metzger-Filho O, Winer EP. The natural history 
of hormone receptor-positive breast cancer. Oncology 
(Williston Park, N.Y.). 2012; 26: 688-94, 696.
5. Tsai MJ, O’Malley BW. Molecular mechanisms of action 
of steroid/thyroid receptor superfamily members. Annual 
Review of Biochemistry. 1994; 63: 451-486.
6. Mohibi S, Mirza S, Band H, Band V. Mouse models 
of estrogen receptor-positive breast cancer. Journal of 
Carcinogenesis. 2011; 10: 35-3163.91116. 
7. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. 
Treatment of estrogen receptor-positive breast cancer. 
Current Medicinal Chemistry. 2013; 20: 596-604.
8. Renoir JM, Marsaud V, Lazennec G. Estrogen receptor 
signaling as a target for novel breast cancer therapeutics. 
Biochemical Pharmacology. 2013; 85: 449-465.
9. Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive 
regulator of transcription. Transcription. 2010; 1: 4-12.
10. Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn 
MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, 
Espinosa JM. HIF1A employs CDK8-mediator to stimulate 
RNAPII elongation in response to hypoxia. Cell. 2013; 153: 
1327-1339.
11. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. CDK8 
is a positive regulator of transcriptional elongation within 
the serum response network. Nature Structural & Molecular 
Biology. 2010; 17: 194-201.
12. McCleland ML, Soukup TM, Liu SD, Esensten JH, de 
Sousa e Melo F, Yaylaoglu M, Warming S, Roose-Girma 
M, Firestein R. Cdk8 deletion in the Apc(Min) murine 
tumour model represses EZH2 activity and accelerates 
tumourigenesis. The Journal of Pathology. 2015; 237: 508-
519.
13. Porter DC, Farmaki E, Altilia S, Schools GP, West DK, 
Chen M, Chang BD, Puzyrev AT, Lim CU, Rokow-Kittell 
R, Friedhoff LT, Papavassiliou AG, Kalurupalle S, et al. 
Cyclin-dependent kinase 8 mediates chemotherapy-induced 
tumor-promoting paracrine activities. Proceedings of the 
National Academy of Sciences of the United States of 
America. 2012; 109: 13799-13804.
14. Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, 
Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi 
O, Christie AL, Du K, Banka D, Schneider EV, et al. 
Mediator kinase inhibition further activates super-enhancer-
associated genes in AML. Nature. 2015; 526: 273-276.
15. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney 
I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, 
Tamayo P, Finn S, et al. CDK8 is a colorectal cancer 
oncogene that regulates beta-catenin activity. Nature. 2008; 
455: 547-551.
16. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa 
S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, 
Sapkota G, Pan D, Massague J. Nuclear CDKs drive Smad 
transcriptional activation and turnover in BMP and TGF-
beta pathways. Cell. 2009; 139: 757-769.
17. Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar 
K, Segura MF, Emanuel PO, Menendez S, Vardabasso 
C, Leroy G, Vidal CI, Polsky D, Osman I, Garcia BA, et 
al. The histone variant macroH2A suppresses melanoma 
progression through regulation of CDK8. Nature. 2010; 
468: 1105-1109.
18. Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, Li Y, 
Tang Y. Mutated K-ras activates CDK8 to stimulate the 
epithelial-to-mesenchymal transition in pancreatic cancer 
in part via the Wnt/beta-catenin signaling pathway. Cancer 
Letters. 2015; 356: 613-627.
19. Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, 
Soukup TM, Roose-Girma M, Blackwood EM, Firestein R. 
CDK8 maintains tumor dedifferentiation and embryonic 
stem cell pluripotency. Cancer Research. 2012; 72: 2129-
2139.
20. Broude EV, Gyorffy B, Chumanevich AA, Chen M, 
McDermott MS, Shtutman M, Catroppo JF, Roninson 
IB. Expression of CDK8 and CDK8-interacting Genes as 
Potential Biomarkers in Breast Cancer. Current Cancer 
Drug Targets. 2015; 15: 739-749.
21. Xu D, Li CF, Zhang X, Gong Z, Chan CH, Lee SW, Jin G, 
Rezaeian AH, Han F, Wang J, Yang WL, Feng ZZ, Chen 
W, et al. Skp2-macroH2A1-CDK8 axis orchestrates G2/M 
transition and tumorigenesis. Nature Communications. 
Oncotarget12575www.impactjournals.com/oncotarget
2015; 6: 6641.
22. Belakavadi M, Fondell JD. Cyclin-dependent kinase 8 
positively cooperates with Mediator to promote thyroid 
hormone receptor-dependent transcriptional activation. 
Molecular and Cellular Biology. 2010; 30: 2437-2448.
23. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan 
PS, Leu YW, Chan MW, Plass C, Nephew KP, Davuluri 
RV, Huang TH. Combinatorial analysis of transcription 
factor partners reveals recruitment of c-MYC to estrogen 
receptor-alpha responsive promoters. Molecular Cell. 2006; 
21: 393-404.
24. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, 
Lippman ME. GREB 1 is a critical regulator of hormone 
dependent breast cancer growth. Breast Cancer Research 
and Treatment. 2005; 92: 141-149.
25. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, 
Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, 
Hall GF, Wang Q, Bekiranov S, Sementchenko V, et al. 
Genome-wide analysis of estrogen receptor binding sites. 
Nature Genetics. 2006; 38: 1289-1297.
26. Sun J, Nawaz Z, Slingerland JM. Long-range activation 
of GREB1 by estrogen receptor via three distal consensus 
estrogen-responsive elements in breast cancer cells. 
Molecular Endocrinology (Baltimore, Md.). 2007; 21: 
2651-2662.
27. Roninson IB, Porter DC, Wentland MP, inventors; 
Senex Biotechnology Inc., assignee. CDK8-CDK19 
selective inhibitors and their use in anti-metastatic and 
chemopreventative methods for cancer. United States patent 
US 9321737B2. 2016 Apr 26.
28. Sikora MJ, Strumba V, Lippman ME, Johnson MD, Rae 
JM. Mechanisms of estrogen-independent breast cancer 
growth driven by low estrogen concentrations are unique 
versus complete estrogen deprivation. Breast Cancer 
Research and Treatment. 2012; 134: 1027-1039.
29. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, 
Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr 
Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 
kinase promotes escape from hormone dependence in 
estrogen receptor-positive human breast cancer. The Journal 
of Clinical Investigation. 2010; 120: 2406-2413.
30. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, 
Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung 
C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, et 
al. CDK7 inhibition suppresses super-enhancer-linked 
oncogenic transcription in MYCN-driven cancer. Cell. 
2014; 159: 1126-1139.
31. Rzymski T, Mikula M, Wiklik K, Brzozka K. CDK8 kinase 
- An emerging target in targeted cancer therapy. Biochimica 
et Biophysica Acta. 2015; 1854: 1617-1629.
32. Xu W, Ji JY. Dysregulation of CDK8 and Cyclin C in 
tumorigenesis. Journal of Genetics and Genomics. 2011; 
38: 439-452.
33. Mallinger A, Schiemann K, Rink C, Stieber F, Calderini 
M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke 
O, Busch M, Czodrowski P, Musil D, Schwarz D, et al. 
Discovery of Potent, Selective, and Orally Bioavailable 
Small-Molecule Modulators of the Mediator Complex-
Associated Kinases CDK8 and CDK19. Journal of 
Medicinal Chemistry. 2016; 59: 1078-1101.
34. Ward RD, Weigel NL. Steroid receptor phosphorylation: 
Assigning function to site-specific phosphorylation. 
BioFactors (Oxford, England). 2009; 35: 528-536.
35. Held JM, Britton DJ, Scott GK, Lee EL, Schilling B, 
Baldwin MA, Gibson BW, Benz CC. Ligand binding 
promotes CDK-dependent phosphorylation of ER-alpha 
on hinge serine 294 but inhibits ligand-independent 
phosphorylation of serine 305. Molecular Cancer Research. 
2012; 10: 1120-1132.
36. Lewis JS, Jordan VC. Selective estrogen receptor 
modulators (SERMs): mechanisms of anticarcinogenesis 
and drug resistance. Mutation Research. 2005; 591: 247-
263.
37. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, 
Li Q, Szallasi Z. An online survival analysis tool to rapidly 
assess the effect of 22,277 genes on breast cancer prognosis 
using microarray data of 1,809 patients. Breast Cancer 
Research and Treatment. 2010; 123: 725-731.
38. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson 
BM, Espinosa JM. Gene-specific requirement for P-TEFb 
activity and RNA polymerase II phosphorylation within the 
p53 transcriptional program. Genes & Development. 2006; 
20: 601-612.
39. R Core Team. R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, 
Vienna, Austria. 
40. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, 
Smyth GK. limma powers differential expression analyses 
for RNA-sequencing and microarray studies. Nucleic Acids 
Research. 2015; 43: e47.
41. Warnes G, Bolker B, Bonebakker L, Gentleman R, Huber 
W, Liaw A, Lumley T, Maechler M, Magnusson A, 
Moeller S, Schwartz M, Venables B. gplots: Various R 
Programming Tools for Plotting Data. R package version 
3.0.1.
42. Chou TC. Drug combination studies and their synergy 
quantification using the Chou-Talalay method. Cancer 
Research. 2010; 70: 440-446.
